Activation of the reticulothalamic cholinergic pathway by the major metabolites of aniracetam

European Journal of Pharmacology

Volumn 380, Issue 2-3, 1999, Pages 81-89

  Nakamura, Kazuo ^a   Shirane, Masatoshi ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

Acetylcholine; Aniracetam; Choline acetyltransferase; Metabolite; Microdialysis; Stroke prone spontaneously hypertensive rat (SHRSP)

Indexed keywords

4 AMINOBUTYRIC ACID; ANIRACETAM; CHOLINE ACETYLTRANSFERASE; DRUG METABOLITE; NOOTROPIC AGENT;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINERGIC TRANSMISSION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; MALE; MICRODIALYSIS; MULTIINFARCT DEMENTIA; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; THALAMUS NUCLEUS;

ACETYLCHOLINE; ANIMALS; ANISOLES; CEREBRAL CORTEX; CHOLINE O-ACETYLTRANSFERASE; HIPPOCAMPUS; HYPERTENSION; LOCOMOTION; MALE; MICRODIALYSIS; MICROINJECTIONS; NOOTROPIC AGENTS; PONS; PREFRONTAL CORTEX; PYRROLIDINONES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TEGMENTUM MESENCEPHALI; THALAMIC NUCLEI; THALAMUS;

EID: 0032837169     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00534-8     Document Type: Article

References (43)

1. Chen J., Delaney K.H., Kwiecien J.M., Lee R.M.K.W. The effects of dietary sodium on hypertension and stroke development in female stroke-prone spontaneously hypertensive rats. Exp. Mol. Pathol. 64:1997;173-183.
2. Egashira T., Takayama F., Yamanaka Y. Effects of bifemelane on muscarinic receptors and choline acetyltrasferase in the brains of aged rats following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries. Jpn. J. Pharmacol. 72(1):1996;57-65.
3. Fujishima M., Ibayashi S., Fujii K., Mori S. Cerebral blood flow and brain function in hypertension. Hypertens. Res. 18:1995;111-117.
4. Gattu M., Pauly J.R., Boss K.L., Summers J.B., Buccafusco J.J. Cognitive impairment in spontaneously hypertensive rats: I. Role of central nicotinic receptors. Brain Res. 771:1997;89-103.
5. Giovannini M.G., Rodinò P., Mutolo D., Pepeu G. Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus in vivo. Drug Dev. Res. 28:1993;503-509.
6. Giovannini M.G., Rakovska A., Della Corta L., Bianchi L., Pepeu G. Activation of non-NMDA receptors stimulates acetylcholine and GABA release from dorsal hippocampus: a microdialysis study in the rat. Neurosci. Lett. 243:1998;152-156.
7. Gottfries C.G., Blennow K., Karlsson I., Wallin A. The neurochemistry of vascular dementia. Dementia. 5:1994;163-167.
8. Hallanger A.E., Levey A.I., Lee H.J., Rye D.B., Wainer B.H. The origins of cholinergic and other subcortical afferents to the thalamus in the rat. J. Comp. Neurol. 262:1987;105-124.
9. Himori N., Imai M., Nakamura Y. Potentiating action of the cerebral insufficiency enhancer, aniracetam, on adenosine triphosphate production in rat brain mitochondria. Pharmacol. Commun. 2:1992;211-216.
10. Honma S., Takei A., Fukuzawa T., Hamada K., Hamada T. Treatment of Parkinson's disease with aniracetam. Aging Diseases. 8:1995;96-99.
11. Houser C.R., Vaughn J.E., Barbar R.P., Roberts E. GABA neurons are the major cell type of the nucleus reticularis thalami. Brain Res. 200:1980;341-354.
12. Jäkälä P., Pjöklund M., Koivisto E., Reikkenen P. Jr. The effects of cholinergic drugs on rat neocortical high-voltage spindles in ketanserin-treated rats. Eur. J. Pharmacol. 316:1996;181-193.
13. Jellinger K. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 51:1988;540-543.
14. Kaneda N., Nagatsu T. Highly sensitive assay for choline acetyltransferase activity in high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 341:1985;23-35.
15. Kang Y.S., Terasaki T., Tsuji A. Dysfunction of choline transport system through blood-brain barrier in stroke-prone spontaneously hypertensive rats. J. Pharmacobio-Dyn. 13:1990;10-19.
16. Katsunuma H., Shimizu T., Ogawa K., Kubo H., Ishida H., Yoshihama A. Treatment of insomnia by concomitant therapy with zopiclone and aniracetam in patients with cerebral infarction, cerebroatrophy, Alzheimer's disease and Parkinson's disease. Psychiatr. Clin. Neurosci. 52(2):1998;198-200.
17. Kendrick K.M., Guevara-Guzman R., de la Riva C., Christensen J., Østergaard K., Emson P.C. NMDA and kinate-evoked release of nitric oxide and classical transmitters in the rat striatum: in vivo evidence that nitric oxide may play a neuroprotective role. Eur. J. Neurosci. 8:1996;2619-2634.
18. Kondoh Y., Asanuma M., Kabuto H., Iwata E., Kondoh F., Miyazaki I., Ogawa N. Aniracetam ameliorates impaired pre- and post-synaptic cholinergic indices in gerbil hippocampus induced by transient forebrain ischemia. J. Brain Sci. 23:1997;250-260.
19. Martin J.R., Haefely W.E. Pharmacology of aniracetam: a novel pyrrolidinone derivative with cognitive enhancing activity. Drug Invest. 5:1993;4-49. suppl. 1.
20. Mayersohn M., Roncari G., Wendt G. Diposition pharmacokinetics and metabolism of aniracetam in animals. Drug Invest. 5:1993;73-95. suppl. 1.
21. Mesulam M.-M., Mufson E.J., Wainer B.H., Levey A.I. Central cholinergic pathways in the rat: an overview based on alternative nomenclature (Ch1-Ch6). Neuroscience. 10:1983;1185-1201.
22. Mesulam M.-M., Guela C., Bothwell M.A., Mersh L.B. Human reticular formation: cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei and some cytochemical comparisons to forebrain cholinergic neurons. J. Comp. Neurol. 283:1989;611-633.
23. Nagasaka T., Togashi S., Amano A., Nitta K., Shindo K., Shiozawa Z. Aniracetam for treatment of patients with progressive supranuclear palsy. Eur. Neurol. 37:1997;195-198.
24. Nakamura K., Kurasawa M., Tanaka Y. Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam. Drug Dev. Res. 43:1998;85-97.
25. Ogiso T., Iwaki M., Tanino T., Ikeda K., Paku T., Horibe Y., Suzuki H. Pharmacokinetics of aniracetam and its metabolites in rats. J. Pharm. Sci. 87:1998;594-598.
26. Otomo E., Hirai S., Terashi A., Hasegawa K., Tazaki Y., Araki G., Itoh E., Nishimura T., Furukawa T. Clinical usefulness of aniracetam for psychiatric symptoms in patients with cerebrovascular disorders: double-blind trial placebo. J. Clin. Exp. Med. (Igaku No Ayumi). 156:1991;143-187.
27. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, New York.
28. Pizzi M., Fallacara C., Arrighi V., Memo M., Spano P.-F. Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. J. Neurochem. 61:1993;683-689.
29. Roncari G. Human pharmacokinetics of aniracetam. Drug Invest. 5:1993;68-72. suppl. 1.
30. Saito, H., Togashi, H., Yoshioka, M., Nakamura, M., Minami, M., Parvez, H., 1995. Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. (Suppl. 1), S257-S259.
31. Sakurada T., Alufuzoff I., Winblad B., Nordberg A. Substance-P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia. Brain Res. 521:1990;329-332.
32. Senin U., Pernet L., Cucinotta D., Crisculo D., Longo A., Marini G. Clinical experience with aniracetam in the treatment of senile dementia of Alzheimer's type and related disorders. Drug Invest. 5:1993;96-105. suppl. 1.
33. Steckler T., Inglis W., Winn P., Sahgal A. The pedunculopontine tegmental nucleus: a role in cognitive processes? Brain Res. Rev. 19:1994;298-318.
34. Steriade M., Datta S., Paré D., Oakson G., Curró Dossi R. Neuronal activities in brainstem cholinergic nuclei related to tonic activation processes in thalamocortical systems. J. Neurosci. 10(8):1990;2541-2559.
35. Steriade, M., Jones, E.G., Llinás, R.R., 1990b. Thalamic Oscillations and Signaling. Wiley, New York.
36. Togashi H., Matsumoto M., Yoshioka M., Hirokami M., Minami M., Saito H. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci. Lett. 166:1994;117-120.
37. Togashi H., Kimura S., Matsumoto M., Yoshioka M., Minami M., Saito H. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke. 27:1996;520-526.
38. Tohgi H., Abe T., Kimura M., Saheki M., Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J. Neural. Transm. 103:1996;1211-1220.
39. Uchida S., Kagitani F., Nakayama H., Sato A. Effect of stimulation of nicotinic cholinergic receptors on cortical cerebral blood flow and changes in the effect during aging in anesthetized rats. Neurosci. Lett. 228:1997;203-206.
40. Woolf N.J., Butcher L.L. Cholinergic systems in the rat brain: III. Projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia and basal forebrain. Brain Res. Bull. 16:1986;603-637.
41. Wultz B., Sagvolden T., Moser E.I., Moser M.-B. The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: Effects of metylphenidate on exploratory behavior. Behav. Neural Biol. 53:1990;88-102.
42. Yamada S., Ishima T., Hayashi M., Tomita T., Hayashi E. Muscarinic cholinoceptors and choline acetyltransferase activity in the hypothalamus of spontaneously hypertensive rats. Life Sci. 34:1984;2151-2158.
43. Yamada S., Kagawa Y., Ushijima H., Takayanagi N., Tomita T., Hayashi E. Brain nicotinic cholinoceptor binding in spontaneous hypertension. Brain Res. 410:1987;212-218.